Related Experiment Video

Updated: Apr 25, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

15.4K

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study

Jung Han Yoon1, Jin Soo Lee, Seok Woo Yong

  • 1Department of Neurology, Ajou University School of Medicine, Suwon, South Korea.

Movement Disorders : Official Journal of the Movement Disorder Society
|August 27, 2014
PubMed

Insights

Levodopa (l-dopa) therapy for Parkinson's disease (PD) may cause endothelial dysfunction by increasing homocysteine levels. This study found impaired flow-mediated dilation in PD patients on l-dopa, suggesting a link to treatment.

Area of Science:

  • Neurology
  • Cardiovascular Science
  • Pharmacology

Background:

  • Parkinson's disease (PD) treatment with levodopa (l-dopa) is associated with elevated serum homocysteine.
  • Elevated homocysteine is a potential risk factor for endothelial dysfunction.

Purpose of the Study:

  • To investigate the association between levodopa treatment, homocysteine levels, and endothelial function in Parkinson's disease patients.
  • To compare endothelial function (flow-mediated dilation) across different PD treatment groups and controls.

Main Methods:

  • Cross-sectional study comparing flow-mediated dilation (FMD) in four groups: PD patients on l-dopa, PD patients on l-dopa/entacapone, untreated PD patients, and healthy controls.
  • Serum homocysteine levels were measured and correlated with FMD.

Main Results:

  • PD patients on l-dopa exhibited significantly lower FMD compared to those on l-dopa/entacapone, untreated PD patients, and controls.
  • Higher homocysteine levels were observed in PD patients treated with l-dopa.
  • Elevated homocysteine was an independent predictor of reduced flow-mediated dilation.

Conclusions:

  • Chronic levodopa treatment in Parkinson's disease may be linked to endothelial dysfunction.
  • Increased homocysteine levels during levodopa therapy could contribute to endothelial impairment in PD patients.
Abstract

Keywords:
Parkinson's diseaseendothelial dysfunctionflow-mediated dilationhyperhomocysteinemia

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

45.2K
Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

26.8K

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
16
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.7K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
756